Richard E Lee

List of Publications by Year
in descending order

188	10,102	33666	41354
papers	citations	51 h-index	91 g-index

197	197	197	11989
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nature Reviews Microbiology, 2011, 9, 62-75.	28.9	692
2	Mycolic acids: structure, biosynthesis and physiological functions. Progress in Lipid Research, 1998, 37, 143-179.	12.1	512
3	Validation of Molecular Docking Programs for Virtual Screening against Dihydropteroate Synthase. Journal of Chemical Information and Modeling, 2009, 49, 444-460.	5.6	398
4	Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nature Chemical Biology, 2012, 8, 334-341.	8.0	393
5	Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1345-1349.	7.5	350
6	Genome-Wide Expression Profiling of the Response to Azole, Polyene, Echinocandin, and Pyrimidine Antifungal Agents in Candida albicans. Antimicrobial Agents and Chemotherapy, 2005, 49, 2226-2236.	3.4	322
7	New agents for the treatment of drug-resistant Mycobacterium tuberculosis. Advanced Drug Delivery Reviews, 2016, 102, 55-72.	14.2	274
8	Combinatorial Lead Optimization of [1,2]-Diamines Based on Ethambutol as Potential Antituberculosis Preclinical Candidates. ACS Combinatorial Science, 2003, 5, 172-187.	3.4	205
9	Novel Insights into the Mechanism of Inhibition of MmpL3, a Target of Multiple Pharmacophores in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2014, 58, 6413-6423.	3.4	174
10	Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux. Nature Medicine, 2014, 20, 152-158.	29.9	165
11	Heterogeneity of Mycolactones Produced by Clinical Isolates of Mycobacterium ulcerans : Implications for Virulence. Infection and Immunity, 2003, 71, 774-783.	2.3	158
12	Novel inhibitors of an emerging target in Mycobacterium tuberculosis; substituted thiazolidinones as inhibitors of dTDP-rhamnose synthesis. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 3227-3230.	2.3	155
13	Acyl-Phosphates Initiate Membrane Phospholipid Synthesis in Gram-Positive Pathogens. Molecular Cell, 2006, 23, 765-772.	9.5	152
14	Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis. Molecular Microbiology, 2000, 38, 514-525.	2.5	138
15	Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs. Biochemical Pharmacology, 2000, 59, 221-231.	4.5	125
16	Globally Distributed Mycobacterial Fish Pathogens Produce a Novel Plasmid-Encoded Toxic Macrolide, Mycolactone F. Infection and Immunity, 2006, 74, 6037-6045.	2.3	122
17	Inhibition of UDP-Gal Mutase and Mycobacterial Galactan Biosynthesis by Pyrrolidine Analogues of Galactofuranose. Tetrahedron Letters, 1997, 38, 6733-6736.	1.4	112
18	A Newly Discovered Mycobacterial Pathogen Isolated from Laboratory Colonies of Xenopus Species with Lethal Infections Produces a Novel Form of Mycolactone, the Mycobacterium ulcerans Macrolide Toxin. Infection and Immunity, 2005, 73, 3307-3312.	2.3	112

#	Article	IF	Citations
19	Chemical Knockout of Pantothenate Kinase Reveals the Metabolic and Genetic Program Responsible for Hepatic Coenzyme A Homeostasis. Chemistry and Biology, 2007, 14, 291-302.	6.2	107
20	Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3. Antimicrobial Agents and Chemotherapy, 2016, 60, 5198-5207.	3.4	103
21	Crystal Structure of 7,8-Dihydropteroate Synthase from Bacillus anthracis. Structure, 2004, 12, 1705-1717.	3.3	97
22	A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. Journal of Antimicrobial Chemotherapy, 2008, 62, 1037-1045.	3.2	95
23	Synthesis and Evaluation of Cyclic Secondary Amine Substituted Phenyl and Benzyl Nitrofuranyl Amides as Novel Antituberculosis Agents. Journal of Medicinal Chemistry, 2005, 48, 8261-8269.	6.6	93
24	Discovery of Novel Selective Inhibitors of Human Intestinal Carboxylesterase for the Amelioration of Irinotecan-Induced Diarrhea: Synthesis, Quantitative Structure-Activity Relationship Analysis, and Biological Activity. Molecular Pharmacology, 2004, 65, 1336-1343.	2.3	92
25	Design, synthesis, and biological evaluation of curcumin analogues as multifunctional agents for the treatment of Alzheimerâ€™s disease. Bioorganic and Medicinal Chemistry, 2011, 19, 5596-5604.	3.1	89
26	Synthesis, Structureâ€“Activity Relationship Studies, and Antibacterial Evaluation of 4-Chromanones and Chalcones, as Well as Olympicin A and Derivatives. Journal of Medicinal Chemistry, 2014, 57, 8398-8420.	6.6	89
27	Mycobacterial arabinan biosynthesis: the use of synthetic arabinoside acceptors in the development of an arabinosyl transfer assay. Glycobiology, 1997, 7, 1121-1128.	2.8	86
28	A Pantothenate Kinase from Staphylococcus aureus Refractory to Feedback Regulation by Coenzyme A. Journal of Biological Chemistry, 2005, 280, 3314-3322.	3.5	86
29	Discovery of novel isoxazolines as anti-tuberculosis agents. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6638-6642.	2.3	84
30	A statistical framework to evaluate virtual screening. BMC Bioinformatics, 2009, 10, 225.	2.6	84
31	Pantothenamides Are Potent, On-Target Inhibitors of Plasmodium falciparum Growth When Serum Pantetheinase Is Inactivated. PLoS ONE, 2013, 8, e54974.	2.5	84
32	New Approaches to Target the Mycolic Acid Biosynthesis Pathway for the Development of Tuberculosis Therapeutics. Current Pharmaceutical Design, 2013, 20, 4357-4378.	1.8	84
33	Synthesis and Evaluation of Nitrofuranylamides as Novel Antituberculosis Agents. Journal of Medicinal Chemistry, 2004, 47, 5276-5283.	6.6	82
34	RelA Mutant Enterococcus faecium with Multiantibiotic Tolerance Arising in an Immunocompromised Host. MBio, 2017, 8, .	4.3	80
35	Identification of triazinoindol-benzimidazolones as nanomolar inhibitors of the Mycobacterium tuberculosis enzyme TDP-6-deoxy-d-xylo-4-hexopyranosid-4-ulose 3,5-epimerase (RmlC). Bioorganic and Medicinal Chemistry, 2010, 18, 896-908.	3.1	79
36	Mechanisms involved in the intrinsic isoniazid resistance ofMycobacterium avium. Molecular Microbiology, 1998, 27, 1223-1233.	2.5	78

#	Article	IF	Citations
37	Pterinâ€“sulfa conjugates as dihydropteroate synthase inhibitors and antibacterial agents. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3950-3954.	2.3	77
38	Acyl Carrier Protein Is a Cellular Target for the Antibacterial Action of the Pantothenamide Class of Pantothenate Antimetabolites. Journal of Biological Chemistry, 2004, 279, 50969-50975.	3.5	76
39	Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability. Bioorganic and Medicinal Chemistry, 2012, 20, 3255-3262.	3.1	75
40	Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties. Bioorganic and Medicinal Chemistry, 2013, 21, 2587-2599.	3.1	74
41	A therapeutic approach to pantothenate kinase associated neurodegeneration. Nature Communications, 2018, 9, 4399.	13.0	71
42	Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6973-6976.	2.3	66
43	The Structural and Functional Basis for Recurring Sulfa Drug Resistance Mutations in Staphylococcus aureus Dihydropteroate Synthase. Frontiers in Microbiology, 2018, 9, 1369.	3.5	65
44	Phenylâ€Glutarimides: Alternative Cereblon Binders for the Design of PROTACs. Angewandte Chemie - International Edition, 2021, 60, 26663-26670.	14.6	63
45	Structureâ€“activity relationships and enzyme inhibition of pantothenamide-type pantothenate kinase inhibitors. Bioorganic and Medicinal Chemistry, 2006, 14, 1007-1020.	3.1	62
46	Synthesis, optimization and structureâ€“activity relationships of 3,5-disubstituted isoxazolines as new anti-tuberculosis agents. European Journal of Medicinal Chemistry, 2009, 44, 460-472.	5.7	62
47	Covalent Modification of the Mycobacterium tuberculosis FAS-II Dehydratase by Isoxyl and Thiacetazone. ACS Infectious Diseases, 2015, 1, 91-97.	3.9	62
48	Rapid structural characterization of the arabinogalactan and lipoarabinomannan in live mycobacterial cells using 2D and 3D HR-MAS NMR: structural changes in the arabinan due to ethambutol treatment and gene mutation are observed. Glycobiology, 2004, 15, 139-151.	2.8	56
49	Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for Research. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 947-951.	6.4	56
50	Design, synthesis, and evaluation of novel ethambutol analogues. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1607-1611.	2.3	55
51	Genome-wide expression profiling of the response to ciclopirox olamine in Candida albicans. Journal of Antimicrobial Chemotherapy, 2005, 55, 655-662.	3.2	54
52	In Vitro Pharmacokinetic/Pharmacodynamic Models in Anti-Infective Drug Development: Focus on TB. Future Medicinal Chemistry, 2010, 2, 1355-1369.	2.3	54
53	Structural Characterization of the Mycobacterium tuberculosis Biotin Biosynthesis Enzymes 7,8-Diaminopelargonic Acid Synthase and Dethiobiotin Synthetase,. Biochemistry, 2010, 49, 6746-6760.	2.6	53
54	Synthesis, antitubercular activity, and SAR study of N-substituted-phenylamino-5-methyl-1H-1,2,3-triazole-4-carbohydrazides. Bioorganic and Medicinal Chemistry, 2011, 19, 5605-5611.	3.1	53

#	Article	IF	Citations
55	Discovery of non-carbohydrate inhibitors of aminoglycoside-modifying enzymes. Bioorganic and Medicinal Chemistry, 2005, 13, 6252-6263.	3.1	51
56	An approach to combinatorial library generation of galactofuranose mimics as potential inhibitors of mycobacterial cell wall biosynthesis: Synthesis of a peptidomimetic of uridine 5â€²-diphosphogalactofuranose (UDP-Galf). Tetrahedron Letters, 1999, 40, 8689-8692.	1.4	50
57	The Structure of the Pantothenate KinaseÂ·ADPÂ·Pantothenate Ternary Complex Reveals the Relationship between the Binding Sites for Substrate, Allosteric Regulator, and Antimetabolites. Journal of Biological Chemistry, 2004, 279, 35622-35629.	3.5	49
58	Replacing Sulfa Drugs with Novel Dhps Inhibitors. Future Medicinal Chemistry, 2013, 5, 1331-1340.	2.3	49
59	Quantitative structureâ€“activity relationship studies on nitrofuranyl anti-tubercular agents. Bioorganic and Medicinal Chemistry, 2008, 16, 8042-8053.	3.1	46
60	Structures of trehalose-6-phosphate phosphatase from pathogenic fungi reveal the mechanisms of substrate recognition and catalysis. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 7148-7153.	7.5	46
61	Synthesis of new and potent analogues of anti-tuberculosis agent 5-nitro-furan-2-carboxylic acid 4-(4-benzyl-piperazin-1-yl)-benzylamide with improved bioavailability. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 2584-2589.	2.3	44
62	In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis Antibiotics. Scientific Reports, 2015, 5, 13985.	3.4	43
63	Novel Acyl Phosphate Mimics that Target PlsY, an Essential Acyltransferase in Gramâ€Positive Bacteria. ChemMedChem, 2008, 3, 1936-1945.	3.4	42
64	N-Substituted 3-Acetyltetramic Acid Derivatives as Antibacterial Agents. Journal of Medicinal Chemistry, 2008, 51, 1487-1491.	6.6	42
65	Detection of Mycolactone A/B in Mycobacterium ulceransâ€“Infected Human Tissue. PLoS Neglected Tropical Diseases, 2010, 4, e577.	2.4	42
66	Structureâ€“Activity Relationships of Spectinamide Antituberculosis Agents: A Dissection of Ribosomal Inhibition and Native Efflux Avoidance Contributions. ACS Infectious Diseases, 2017, 3, 72-88.	3.9	41
67	Nitrofurans as Novel Anti-tuberculosis Agents: Identification, Development and Evaluation. Current Topics in Medicinal Chemistry, 2007, 7, 509-526.	2.0	40
68	Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties. Bioorganic and Medicinal Chemistry, 2012, 20, 6063-6072.	3.1	39
69	Biological control of sclerotinia stem rot of canola using antagonistic bacteria. Plant Pathology, 2015, 64, 1375-1384.	2.4	38
70	Biopharmaceutics, Pharmacokinetics and Pharmacodynamics of Antituberculosis Drugs. Current Medicinal Chemistry, 2008, 15, 809-825.	2.4	35
71	Metabolic Activation of CaMKII by Coenzyme A. Molecular Cell, 2013, 52, 325-339.	9.5	35
72	Identification and Characterization of an Allosteric Inhibitory Site on Dihydropteroate Synthase. ACS Chemical Biology, 2014, 9, 1294-1302.	3.5	35

#	Article	IF	Citations
73	Topology and Active Site of PlsY. Journal of Biological Chemistry, 2007, 282, 11339-11346.	3.5	34
74	Pharmacokinetically-Guided Lead Optimization of Nitrofuranylamide Anti-Tuberculosis Agents. AAPS Journal, 2008, 10, 157-165.	4.7	34
75	A rapid approach to lipid profiling of mycobacteria using 2D HSQC NMR maps. Journal of Lipid Research, 2008, 49, 455-463.	4.2	34
76	A simple in vitro PK/PD model system to determine timeâ€“kill curves of drugs against Mycobacteria. Tuberculosis, 2009, 89, 378-385.	2.0	33
77	Potentiation of Azole Antifungals by 2-Adamantanamine. Antimicrobial Agents and Chemotherapy, 2013, 57, 3585-3592.	3.4	33
78	Characterization of the in vitro synthesized arabinan of mycobacterial cell walls. Biochimica Et Biophysica Acta - General Subjects, 1997, 1335, 231-234.	2.4	32
79	Methods for Acquisition and Assignment of Multidimensional High-Resolution Magic Angle Spinning NMR of Whole Cell Bacteria. Analytical Chemistry, 2005, 77, 5785-5792.	6.7	32
80	Allosteric Regulation of Mammalian Pantothenate Kinase. Journal of Biological Chemistry, 2016, 291, 22302-22314.	3.5	32
81	De Novo Design of Boron-Based Peptidomimetics as Potent Inhibitors of Human ClpP in the Presence of Human ClpX. Journal of Medicinal Chemistry, 2019, 62, 6377-6390.	6.6	32
82	Structureâ€Based Design of Novel Pyrimido[4,5â€c]pyridazine Derivatives as Dihydropteroate Synthase Inhibitors with Increased Affinity. ChemMedChem, 2012, 7, 861-870.	3.4	31
83	The membrane as a target for controlling hypervirulent Clostridium difficile infections. Journal of Antimicrobial Chemotherapy, 2013, 68, 806-815.	3.2	31
84	Ureadepsipeptides as ClpP Activators. ACS Infectious Diseases, 2019, 5, 1915-1925.	3.9	31
85	Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer. Cancer Research, 2020, 80, 3507-3518.	0.9	31
86	Acryloyl Chloride: An Excellent Substrate for Cross-Metathesis. A One-Pot Sequence for the Synthesis of Substituted Î±,Î²-Unsaturated Carbonyl Derivatives. Organic Letters, 2009, 11, 5446-5448.	4.7	30
87	Solid-phase synthesis and biological evaluation of a uridinyl branched peptide urea library. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6899-6904.	2.3	29
88	Synthesis and Structure of Mycolactone E Isolated from Frog Mycobacterium. Organic Letters, 2008, 10, 5385-5388.	4.7	29
89	A Screen for and Validation of Prodrug Antimicrobials. Antimicrobial Agents and Chemotherapy, 2014, 58, 1410-1419.	3.4	29
90	Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw467.	3.2	29

#	Article	IF	Citations
91	The Isoniazid Metabolites Hydrazine and Pyridoxal Isonicotinoyl Hydrazone Modulate Heme Biosynthesis. Toxicological Sciences, 2019, 168, 209-224.	3.1	29
92	Chemical Modulation of the Biological Activity of Reutericyclin: a Membrane-Active Antibiotic from Lactobacillusreuteri. Scientific Reports, 2014, 4, 4721.	3.4	28
93	Synthesis and evaluation of pretomanid (PA-824) oxazolidinone hybrids. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 388-391.	2.3	28
94	Structural and In Vivo Studies on Trehalose-6-Phosphate Synthase from Pathogenic Fungi Provide Insights into Its Catalytic Mechanism, Biological Necessity, and Potential for Novel Antifungal Drug Design. MBio, 2017, 8, .	4.3	28
95	Crystal Structure of the Anthrax Drug Target, Bacillus anthracis Dihydrofolate Reductase. Journal of Medicinal Chemistry, 2007, 50, 4374-4381.	6.6	27
96	Gastrointestinal localization of metronidazole by a lactobacilli-inspired tetramic acid motif improves treatment outcomes in the hamster model ofClostridium difficileinfection. Journal of Antimicrobial Chemotherapy, 2015, 70, 3061-3069.	3.2	27
97	Crystal Structure of the 6-Hydroxymethyl-7,8-Dihydropterin PyrophosphokinaseâC¢Dihydropteroate Synthase Bifunctional Enzyme from Francisella tularensis. PLoS ONE, 2010, 5, e14165.	2.5	26
98	Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 25-36.	3.1	25
99	Pentacyclic Nitrofurans with In Vivo Efficacy and Activity against Nonreplicating Mycobacterium tuberculosis. PLoS ONE, 2014, 9, e87909.	2.5	24
100	Development of BODIPY FL Vindoline as a Novel and High-Affinity Pregnane X Receptor Fluorescent Probe. Bioconjugate Chemistry, 2014, 25, 1664-1677.	3.8	24
101	Translational PK/PD of anti-infective therapeutics. Drug Discovery Today: Technologies, 2016, 21-22, 41-49.	4.2	24
102	Aminomethyl Spectinomycins as Therapeutics for Drug-Resistant Gonorrhea and Chlamydia Coinfections. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.4	24
103	In Vivo and In Vitro Effects of a ClpP-Activating Antibiotic against Vancomycin-Resistant Enterococci. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.4	24
104	Pharmacophore Modeling, Synthesis, and Antibacterial Evaluation of Chalcones and Derivatives. ACS Omega, 2018, 3, 18343-18360.	3.6	23
105	A Structure-based Design Approach for Generating High Affinity BRD4 D1-Selective Chemical Probes. Journal of Medicinal Chemistry, 2022, 65, 2342-2360.	6.6	23
106	Mycolic acid biosynthesis: definition and targeting of the Claisen condensation step. Lipids and Lipid Metabolism, 1997, 1346, 275-284.	2.3	22
107	Activation of Exogenous Fatty Acids to Acyl-Acyl Carrier Protein Cannot Bypass FabI Inhibition in Neisseria. Journal of Biological Chemistry, 2016, 291, 171-181.	3.5	22
108	SB-224289 Antagonizes the Antifungal Mechanism of the Marine Depsipeptide Papuamide A. PLoS ONE, 2016, 11, e0154932.	2.5	22

#	Article	IF	Citations
109	Novel Polyoxyethylene-Containing Glycolipids Are Synthesized inCorynebacterium matruchotiiandMycobacterium smegmatisCultured in the Presence of Tween 80. Journal of Lipids, 2011, 2011, 1-12.	4.9	21
110	Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinamide 1599. Pharmaceutical Research, 2019, 36, 136.	3.5	21
111	Design, synthesis, and biological evaluation of imidazoline derivatives as p53â€“MDM2 binding inhibitors. Bioorganic and Medicinal Chemistry, 2011, 19, 5454-5461.	3.1	20
112	Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives. Expert Review of Clinical Pharmacology, 2013, 6, 159-170.	3.2	20
113	A genome-wide atlas of antibiotic susceptibility targets and pathways to tolerance. Nature Communications, 2022, 13, .	13.0	20
114	Enhanced Photoelectrochemical Activity of 120 MeV Ag⁹⁺ Irradiated Nanostructured Thin Films of ZnO for Solar-Hydrogen Generation via Splitting of Water. Advanced Materials Research, 2009, 67, 95-102.	0.1	19
115	Design, synthesis and microbiological evaluation of ampicillinâ€“tetramic acid hybrid antibiotics. Journal of Antibiotics, 2017, 70, 65-72.	2.0	19
116	CINPA1 binds directly to constitutive androstane receptor and inhibits its activity. Biochemical Pharmacology, 2018, 152, 211-223.	4.5	19
117	Nonfactorization of four-quark condensates at low energies within chiral perturbation theory. Physical Review D, 2010, 82, .	4.7	18
118	Synthesis of bi-substrate state mimics of dihydropteroate synthase as potential inhibitors and molecular probes. Bioorganic and Medicinal Chemistry, 2011, 19, 1298-1305.	3.1	18
119	Acyl-sulfamates target the essential glycerol-phosphate acyltransferase (PlsY) in Gram-positive bacteria. Bioorganic and Medicinal Chemistry, 2012, 20, 4985-4994.	3.1	18
120	Analysis of Mycobacterium Species for the Presence of a Macrolide Toxin, Mycolactone. Infection and Immunity, 2004, 72, 123-132.	2.3	17
121	Solid-Phase Synthesis of a Thymidinyl Dipeptide Urea Library. ACS Combinatorial Science, 2007, 9, 370-385.	3.4	17
122	Aminomethyl spectinomycins as therapeutics for drug-resistant respiratory tract and sexually transmitted bacterial infections. Science Translational Medicine, 2015, 7, 288ra75.	13.3	17
123	Solid-Phase Synthesis and Antibacterial Activity of Cyclohexapeptide Wollamide B Analogs. ACS Combinatorial Science, 2018, 20, 172-185.	3.8	17
124	Discovery and Characterization of the Antimetabolite Action of Thioacetamide-Linked 1,2,3-Triazoles as Disruptors of Cysteine Biosynthesis in Gram-Negative Bacteria. ACS Infectious Diseases, 2020, 6, 467-478.	3.9	17
125	Structural basis for substrate recognition and chemical inhibition of oncogenic MAGE ubiquitin ligases. Nature Communications, 2020, 11, 4931.	13.0	17
126	Novel Cassette Assay To Quantify the Outer Membrane Permeability of Five Î²-Lactams Simultaneously in Carbapenem-Resistant Klebsiella pneumoniae and Enterobacter cloacae. MBio, 2020, 11, .	4.3	17

#	Article	IF	Citations
127	Pantothenate kinase activation relieves coenzyme A sequestration and improves mitochondrial function in mice with propionic acidemia. Science Translational Medicine, 2021, 13, eabf5965.	13.3	17
128	In Vitro Activities of Telavancin and Six Comparator Agents against Anaerobic Bacterial Isolates. Antimicrobial Agents and Chemotherapy, 2009, 53, 3996-4001.	3.4	16
129	Syntheses and evaluation of macrocyclic engelhardione analogs as antitubercular and antibacterial agents. Journal of Antibiotics, 2013, 66, 319-325.	2.0	16
130	Mechanisms of Resistance Associated with the Inhibition of the Dehydration Step of Type II Fatty Acid Synthase in Mycobacterium tuberculosis. ACS Infectious Diseases, 2020, 6, 195-204.	3.9	15
131	The identification, analysis and structure-based development of novel inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase. Bioorganic and Medicinal Chemistry, 2014, 22, 2157-2165.	3.1	14
132	A Fluorescent Probe for Detecting Mycobacterium tuberculosis and Identifying Genes Critical for Cell Entry. Frontiers in Microbiology, 2016, 7, 2021.	3.5	14
133	Preclinical Evaluation of Inhalational Spectinamide-1599 Therapy against Tuberculosis. ACS Infectious Diseases, 2021, 7, 2850-2863.	3.9	14
134	Ertapenem in plasma and peritoneal fluid from patients with severe intra-abdominal infections. Journal of Antimicrobial Chemotherapy, 2011, 66, 1934-1936.	3.2	13
135	Phase II metabolic pathways of spectinamide antitubercular agents: a comparative study of the reactivity of 4-substituted pyridines to glutathione conjugation. MedChemComm, 2016, 7, 114-117.	3.4	12
136	Synthesis and Evaluation of Thiazolidine Amide and Nâ€Thiazolyl Amide Fluoroquinolone Derivatives. Archiv Der Pharmazie, 2017, 350, e201700029.	4.4	12
137	Comparative pharmacokinetics of spectinamide 1599 after subcutaneous and intrapulmonary aerosol administration in mice. Tuberculosis, 2019, 114, 119-122.	2.0	12
138	Aminomethyl spectinomycins: a novel antibacterial chemotype for biothreat pathogens. Journal of Antibiotics, 2019, 72, 693-701.	2.0	12
139	Development of BODIPY FL Thalidomide As a High-Affinity Fluorescent Probe for Cereblon in a Time-Resolved Fluorescence Resonance Energy Transfer Assay. Bioconjugate Chemistry, 2020, 31, 2564-2575.	3.8	12
140	Identification of Inhibitors of Fungal Fatty Acid Biosynthesis. ACS Infectious Diseases, 2021, 7, 3210-3223.	3.9	12
141	Synthesis and evaluation of esters and carbamates to identify critical functional groups for esterase-specific metabolism. Bioorganic and Medicinal Chemistry, 2003, 11, 3237-3244.	3.1	11
142	Solid-phase synthesis development of a thymidinyl and 2â€²-deoxyuridinyl Ugi library for anti-bacterial agent screening. Tetrahedron Letters, 2005, 46, 8497-8501.	1.4	11
143	Do big boats tow big nets?. ICES Journal of Marine Science, 2011, 68, 1663-1669.	2.5	11
144	Advances in Drug Discovery and Development for Pediatric Tuberculosis. Mini-Reviews in Medicinal Chemistry, 2016, 16, 481-497.	2.6	11

#	Article	IF	Citations
145	Azaindole Based Potentiator of Antibiotics against Gram-Negative Bacteria. ACS Infectious Diseases, 2021, 7, 3009-3024.	3.9	11
146	3D QSAR of novel estrogenâ€"RGD peptide conjugates: Getting insight into structural dependence of anti-osteoporosis activity and side effect of estrogen in ERT. Bioorganic and Medicinal Chemistry, 2009, 17, 3680-3689.	3.1	10
147	Development of a Pterin-Based Fluorescent Probe for Screening Dihydropteroate Synthase. Bioconjugate Chemistry, 2011, 22, 2110-2117.	3.8	10
148	Discovery of novel bacterial elongation condensing enzyme inhibitors by virtual screening. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2585-2588.	2.3	10
149	Identification of Small Molecules Exhibiting Oxacillin Synergy through a Novel Assay for Inhibition of vraTSR Expression in Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.4	10
150	Combating Multidrugâ€Resistant Bacteria by Integrating a Novel Target Site Penetration and Receptor Binding Assay Platform Into Translational Modeling. Clinical Pharmacology and Therapeutics, 2021, 109, 1000-1020.	4.9	10
151	Relief of <scp>CoA</scp> sequestration and restoration of mitochondrial function in a mouse model of propionic acidemia. Journal of Inherited Metabolic Disease, 2023, 46, 28-42.	3.6	10
152	In Vitro and In Vivo Activities of HPi1, a Selective Antimicrobial against Helicobacter pylori. Antimicrobial Agents and Chemotherapy, 2014, 58, 3255-3260.	3.4	9
153	Dynamic time-kill curve characterization of spectinamide antibiotics 1445 and 1599 for the treatment of tuberculosis. European Journal of Pharmaceutical Sciences, 2019, 127, 233-239.	4.1	9
154	FPGA implementation of an automatic wheezing detection system. Biomedical Signal Processing and Control, 2018, 46, 76-85.	5.9	8
155	The Discovery and Development of Thienopyrimidines as Inhibitors of Helicobacter pylori That Act through Inhibition of the Respiratory Complex I. ACS Infectious Diseases, 2021, 7, 1044-1058.	3.9	8
156	Synthesis, antibacterial action, and ribosome inhibition of deoxyspectinomycins. Journal of Antibiotics, 2021, 74, 381-396.	2.0	8
157	Model-Based Exposure-Response Assessment for Spectinamide 1810 in a Mouse Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0174420.	3.4	8
158	6-Amino-4-oxo-1,3-diphenyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carbonyl derivatives as a new class of potent inhibitors of Interleukin-8-induced neutrophil chemotaxis. Bioorganic and Medicinal Chemistry, 2009, 17, 3580-3587.	3.1	7
159	Evaluating and evolving a screening library in academia: the St Jude approach. Drug Discovery Today, 2021, 26, 1060-1069.	6.6	7
160	Biophysical analysis of the Mycobacteria tuberculosis peptide binding protein DppA reveals a stringent peptide binding pocket. Tuberculosis, 2022, 132, 102157.	2.0	7
161	Lipid Profiling Using Two-Dimensional Heteronuclear Single Quantum Coherence NMR. Methods in Molecular Biology, 2009, 579, 89-102.	0.7	6
162	Synthesis and antibacterial evaluation of macrocyclic diarylheptanoid derivatives. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4070-4076.	2.3	6

#	Article	IF	Citations
163	Tissue Penetration of a Novel Spectinamide Antibiotic for the Treatment of Tuberculosis. AAPS Journal, 2016, 18, 788-791.	4.7	5
164	Pentacyclic nitrofurans that rapidly kill nifurtimox-resistant trypanosomes. Journal of Antimicrobial Chemotherapy, 2016, 71, 956-963.	3.2	5
165	Exposure of Methicillin-Resistant Staphylococcus aureus to Low Levels of the Antibacterial THAM-3Î¦G Generates a Small Colony Drug-Resistant Phenotype. Scientific Reports, 2018, 8, 9850.	3.4	5
166	LipE guided discovery of isopropylphenyl pyridazines as pantothenate kinase modulators. Bioorganic and Medicinal Chemistry, 2021, 52, 116504.	3.1	5
167	Synthesis and Structureâ€“Activity Relationship of Thioacetamide-Triazoles against Escherichia coli. Molecules, 2022, 27, 1518.	3.9	5
168	Structureâ€Based Design, Synthesis, and Evaluation of 2â€²â€(2â€Hydroxyethyl)â€2â€²â€deoxyadenosine and the 5â€²â€Diphosphate Derivative as Ribonucleotide Reductase Inhibitors. ChemMedChem, 2009, 4, 1649-1656.	3.4	4
169	Efficacy of Aminomethyl Spectinomycins against Complex Upper Respiratory Tract Bacterial Infections. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.4	4
170	Development of an N-Terminal BRD4 Bromodomain-Targeted Degrader. ACS Medicinal Chemistry Letters, 2022, 13, 1621-1627.	3.0	4
171	New lead elements for histamine H3 receptor ligands in the pyrrolo[2,3-d]pyrimidine class. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2890-2893.	2.3	3
172	Replacement of S14 Protein in Ribosomes of Zinc-Starved Mycobacteria Reduces Spectinamide Sensitivity. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.4	3
173	1,3-Diarylpyrazolyl-acylsulfonamides Target HadAB/BC Complex in Mycobacterium tuberculosis. ACS Infectious Diseases, 2022, 8, 2315-2326.	3.9	3
174	Fragment-Based NMR Screening of the BPTF PHD Finger Methyl Lysine Reader Leads to the First Small-Molecule Inhibitors. ACS Medicinal Chemistry Letters, 2023, 14, 1441-1447.	3.0	3
175	Development of 2nd generation aminomethyl spectinomycins that overcome native efflux in Mycobacterium abscessus. Proceedings of the National Academy of Sciences of the United States of America, 2024, 121, .	7.5	3
176	Mechanistic Insight on the Mode of Action of Colletoic Acid. Journal of Medicinal Chemistry, 2019, 62, 6925-6940.	6.6	2
177	Pantothenate Kinase Activation Restores Brain Coenzyme A in a Mouse Model of Pantothenate Kinase-Associated Neurodegeneration. Journal of Pharmacology and Experimental Therapeutics, 2024, 388, 171-180.	2.4	2
178	Metabolic Activation of CaMKII by Coenzyme A. Molecular Cell, 2013, 52, 468.	9.5	1
179	A Tribute to Amy Anderson (1969â€“2016): Leader, Role Model, and Advocate for Structure-Based Design of New Antimicrobial Agents. ACS Infectious Diseases, 2016, 2, 664-665.	3.9	1
180	Design, synthesis, and activity evaluation of novel erythropoietin mimetic peptides. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3038-3041.	2.3	1

#	Article	IF	Citations
181	Development of a Minimalistic Physiologically Based Pharmacokinetic (mPBPK) Model for the Preclinical Development of Spectinamide Antibiotics. Pharmaceutics, 2023, 15, 1759.	4.5	1
182	Sophisticated natural products as antibiotics. Nature, 2024, 632, 39-49.	35.8	1
183	Fragment-Based Approach Identifies a Novel Inhibitory Site on DHPS. Biophysical Journal, 2013, 104, 403a.	0.5	0
184	Winners of the 2018 JA ÅŒmura Awards for excellence. Journal of Antibiotics, 2019, 72, 783-784.	2.0	0
185	Winners of the 2019 JA ÅŒmura Awards for excellence. Journal of Antibiotics, 2020, 73, 737-738.	2.0	0
186	Lack of Specificity of Phenotypic Screens for Inhibitors of the Mycobacterium tuberculosis FAS-II System. Antimicrobial Agents and Chemotherapy, 2020, 65, .	3.4	0
187	Synthesis and antibacterial action of 3â€™,6â€™-disubstituted spectinomycins. Journal of Antibiotics, 0, , .	2.0	0
188	Development of Brain Penetrant Pyridazine Pantothenate Kinase Activators. Journal of Medicinal Chemistry, 0, , .	6.6	0